Actively Recruiting
Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conduction
Led by Óscar Cano Pérez · Updated on 2026-05-14
120
Participants Needed
3
Research Sites
180 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intraventricular conduction delay alone or in combination with AV conduction delay is associated with a dyssynchronous activation of the ventricles and may result in LV function impairment. Conduction system pacing can restore physiologic ventricular activation in the presence of intraventricular and atrioventricular conduction delays. Patients with intraventricular conduction delay alone or in combination with AV conduction delay who have a permanent pacemaker indication due to intermittent bradycardia and have predominantly intact AV conduction may benefit from continuous CSP.
CONDITIONS
Official Title
Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conduction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Need for cardiac pacing with expected ventricular pacing burden of 10% or less after a 1-month run-in period
- Baseline wide QRS complex (≥150 ms) with normal PR interval or QRS ≥130 ms plus PR ≥230 ms
- Left ventricular ejection fraction (LVEF) of 50% or higher
- Confirmed conduction system pacing criteria met
- Signed and dated informed consent form
You will not qualify if you...
- Pregnant women
- Permanent or long-lasting atrial fibrillation
- Previous pacemaker or implantable cardioverter defibrillator (ICD)
- Unstable angina, acute myocardial infarction, coronary artery bypass surgery, angioplasty, or valve repair/replacement within 90 days before enrollment
- Moderate to severe unrepaired heart valve disease
- Participation in another clinical study that may affect results
- Infiltrative or other genetic/acquired primary heart muscle diseases
- Life expectancy less than 2 years
- Left ventricular ejection fraction (LVEF) less than 50%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Hospital Universitario Virgen de las Nieves
Granada, Andalusia, Spain, 18014
Actively Recruiting
2
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Aragon, Spain, 50009
Actively Recruiting
3
Hospital Universitari i Politècnic La Fe
Valencia, Valencia, Spain, 46026
Actively Recruiting
Research Team
Ó
Óscar Cano, MD, PhD
CONTACT
B
Bernabé López, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here